



: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F : SCHI.0000018734

UHID/MR No Visit ID

Ref Doctor : Dr.SELF Emp/Auth/TPA ID

: SCHIOPV27217

: fbgzdrfh

Collected

: 09/Mar/2024 11:24AM

Received Reported : 09/Mar/2024 12:10PM : 09/Mar/2024 03:41PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240063649



Page 1 of 14





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F : SCHI.0000018734

UHID/MR No Visit ID

: SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected : 09/Mar/2024 11:24AM

Received : 09/Mar/2024 12:10PM Reported : 09/Mar/2024 03:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.9	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	40.00	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.55	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	87.7	fL	83-101	Calculated
MCH	28.3	pg	27-32	Calculated
MCHC	32.2	g/dL	31.5-34.5	Calculated
R.D.W	14.9	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	6,210	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			<u>'</u>
NEUTROPHILS	68.9	%	40-80	Electrical Impedance
LYMPHOCYTES	24.6	%	20-40	Electrical Impedance
EOSINOPHILS	8.0	%	1-6	Electrical Impedance
MONOCYTES	5.2	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4278.69	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1527.66	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	49.68	Cells/cu.mm	20-500	Calculated
MONOCYTES	322.92	Cells/cu.mm	200-1000	Calculated
BASOPHILS	31.05	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.8		0.78- 3.53	Calculated
PLATELET COUNT	225000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	09	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240063649





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734 : SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected

: 09/Mar/2024 11:24AM

Received Reported : 09/Mar/2024 12:10PM : 09/Mar/2024 03:41PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 14







: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734 : SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected

: 09/Mar/2024 11:24AM

Received

: 09/Mar/2024 12:10PM

Reported Status : 09/Mar/2024 03:41PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti		
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination		

Page 4 of 14









: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734 : SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected

Status

: 09/Mar/2024 02:30PM

Received

: 09/Mar/2024 07:30PM

Reported

: 09/Mar/2024 08:55PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING , NAF PLASMA	81	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	96	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist SIN No:PLP1429516





Patient Name : Mrs.SHEETAL SHARMA

Age/Gender : 41 Y 1 M 3 D/F
UHID/MR No : SCHI.0000018734

Visit ID : SCHIOPV27217

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fbgzdrfh Collected : 09/Mar/2024 11:24AM Received : 09/Mar/2024 05:34PM

Reported : 09/Mar/2024 08:41PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.1	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	100	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240029039

Page 6 of 14





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No

: SCHI.0000018734

Visit ID Ref Doctor : SCHIOPV27217

Emp/Auth/TPA ID

: Dr.SELF : fbgzdrfh Collected

: 09/Mar/2024 11:24AM

Received

: 09/Mar/2024 12:11PM

Reported

: 09/Mar/2024 03:45PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE, SERUM	'	'		<u>'</u>
TOTAL CHOLESTEROL	202	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	80	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	65	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	137	mg/dL	<130	Calculated
LDL CHOLESTEROL	121	mg/dL	<100	Calculated
VLDL CHOLESTEROL	16	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.11		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dL. When Triglycerides are more than 400 mg/dL LDL cholesterol is a direct measurement.

Page 7 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04656254





Patient Name : Mrs.SHEETAL SHARMA

Age/Gender : 41 Y 1 M 3 D/F

UHID/MR No : SCHI.0000018734

Visit ID : SCHIOPV27217
Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected : 09/Mar/2024 11:24AM

Received : 09/Mar/2024 12:11PM Reported : 09/Mar/2024 07:12PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.90	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	31	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	30.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	63.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.90	g/dL	6.3-8.2	Biuret
ALBUMIN	4.90	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.00	g/dL	2.0-3.5	Calculated
A/G RATIO	1.63		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI .• Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 8 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04656254





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734

Ref Doctor

: SCHIOPV27217

Emp/Auth/TPA ID

: Dr.SELF : fbgzdrfh Collected

: 09/Mar/2024 11:24AM

Received

: 09/Mar/2024 05:32PM

Reported

Status

: 10/Mar/2024 08:27AM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SEF	RUM		
CREATININE	0.71	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	32.40	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	15.1	mg/dL	8.0 - 23.0	Calculated
URIC ACID	3.93	mg/dL	2.5-6.2	Uricase
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.92	mg/dL	2.5-4.5	PMA Phenol
SODIUM	134.9	mmol/L	135-145	Direct ISE
POTASSIUM	4.6	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	95.8	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.62	g/dL	6.3-8.2	Biuret
ALBUMIN	4.73	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.89	g/dL	2.0-3.5	Calculated
A/G RATIO	1.64		0.9-2.0	Calculated

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BI18706929



Page 9 of 14





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734

Ref Doctor

: SCHIOPV27217

Emp/Auth/TPA ID

: Dr.SELF : fbgzdrfh Collected

: 09/Mar/2024 11:24AM

Received

: 09/Mar/2024 12:11PM

Reported

: 09/Mar/2024 06:10PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	35.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 10 of 14

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:SE04656254





Patient Name : Mrs.SHEETAL SHARMA

Age/Gender : 41 Y 1 M 3 D/F
UHID/MR No : SCHI.0000018734

Visit ID : SCHIOPV27217

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : fbgzdrfh Collected : 09/Mar/2024 11:24AM

Received : 09/Mar/2024 12:11PM Reported : 09/Mar/2024 09:22PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TSI	l), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.04	ng/mL	0.67-1.81	ELFA
THYROXINE (T4, TOTAL)	6.74	μg/dL	4.66-9.32	ELFA
THYROID STIMULATING HORMONE (TSH)	2.110	μIU/mL	0.25-5.0	ELFA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 14









: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No Visit ID : SCHI.0000018734 : SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected

: 09/Mar/2024 11:24AM

Received

: 09/Mar/2024 04:55PM

: Final Report

Reported Status : 09/Mar/2024 07:18PM

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE		<u>'</u>	<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	7.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.010		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				·
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	(
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:UR2301829





: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F : SCHI.0000018734

UHID/MR No Visit ID

: SCHIOPV27217

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : fbgzdrfh

Collected

: 09/Mar/2024 11:24AM

Received Reported : 09/Mar/2024 04:55PM

Status

: 09/Mar/2024 07:18PM

Sponsor Name

: Final Report

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:UF011119

Page 13 of 14







: Mrs.SHEETAL SHARMA

Age/Gender

: 41 Y 1 M 3 D/F

UHID/MR No

: SCHI.0000018734

Visit ID Ref Doctor : SCHIOPV27217

Emp/Auth/TPA ID

: Dr.SELF : fbgzdrfh Collected

: 09/Mar/2024 01:50PM

Received

: 09/Mar/2024 10:40PM : 11/Mar/2024 06:51PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF CYTOLOGY

	CYTOLOGY NO.	L-330-24
I	SPECIMEN	
a	SPECIMEN ADEQUACY	ADEQUATE
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR
c	ENDOCERVICAL-TRANSFORMATION ZONE	ABSENT
d	COMMENTS	SATISFACTORY FOR EVALUATION
II	MICROSCOPY	Smear shows sheets of superficial and intermediate squamous cells.
Ш	RESULT	
a	EPITHEIAL CELL	
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN
	GLANDULAR CELL ABNORMALITIES	NOT SEEN
b	ORGANISM	NIL
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Page 14 of 14









Name : Mrs. Sheetal Sharma

Age: 41 Y

Sex: F

Address: delhi

Plan

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:SCHI.0000018734

OP Number: SCHIOPV27217

Bill No :SCHI-OCR-9755 **Date :** 09.03.2024 11:01

Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT	- PAN INDIA - FY2324
1	GAMMA GLUTAMYL TRANFERASE (GGT)	
2	LIVER FUNCTION TEST (LFT)	
3	GLUCOSE, FASTING	
	HEMOGRAM + PERIPHERAL SMEAR	
7	GYNAECOLOGY CONSULTATION /	
(DIET CONSULTATION EXTEN Ren	
	COMPLETE URINE EXAMINATION	
C	URINE GLUCOSE(POST PRANDIAL) *,	
9	PERIPHERAL SMEAR	
(10	ECG &	
(11	BC PAP TEST- PAPSURE	
12	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
(13	DENTAL CONSULTATION Q, WO 12	
14	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) , 2 1,15 PM	
1.5	URINE GLUCOSE(FASTING)	
(10	SONO MAMOGRAPHY - SCREENING	
17	HbA1c, GLYCATED HEMOGLOBIN	
	X-RAY CHEST PA	
(19	ENT CONSULTATION VO CAPTURE	
20	CARDIAC STRESS TEST(TMT)	
2	FITNESS BY GENERAL PHYSICIAN	
22	BLOOD GROUP ABO AND RH FACTOR	
23	LIPID PROFILE /	
_	BODY MASS INDEX (BMI)	
(2:	OPTHAL BY GENERAL PHYSICIAN	
(20	ULTRASOUND - WHOLE ABDOMEN 6	
27	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	

from

Height: U2-5-C3
Weight: U2-5-C3
Pulse: Q-9-

Client Name ARCOFEMI HEALTHCARE LIMITED Patient Name MS. SHARMA SHEI





Unique Identification Authority of India Government of India

नामांकन क्रम / Enrollment No.: 0000/00595/49749

To शीतल शर्मा Sheetal Sharma C/O Sheetal Sharma 32 D First Floor Saket 22 D First Floor Saket
Greenfield Public School Saket
Saket (South Delhi)
Malviya Nagar
South Delhi South Delhi Delhi

6 110017 6 9813304555 ME824573190FH



आपका आधार क्रमांक / Your Aadhaar No. :

8984 1547 4830



भारत सरकार Government of India

शीतल शर्मा Sheetal Sharma जन्म तिथि / DOB : 06/02/1983 महिला / Female

LMP- 4.3.24 P. L. /min/ w/ Specialists in Surgery sharma 414V/F Janu- Hm/CAD

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.





Apollo Clinic

CONSENT FORM

Patient Name:	Age:	
UHID Number:	Company Name:	
I Mr/Mrs/Ms	Employee of	
I Mr/Mrs/Ms(Company) Want to inform you that I am not	interested in gettingSo.V	a Mariografi
Tests done which is a part of my routine heal	lth check package.	
And I claim the above statement in my full co	onsciousness.	
		(
Patient Signature:	Date:	3/24





Consulleton lendery

CERTIFICATE OF MEDICAL FITNESS

This is to certify that I have conducted the clinical examination

		T
•	Medically Fit	-
•	Fit with restrictions/recommendations	
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
	1	
	2	
	3	
	However the employee should follow the advice/medication that has been communicated to him/her.	
	Review after	
•	Currently Unfit.	+
	Review after recommended	

Medical Officer
The Apello Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

NAME :- Que o	tel Sharm	O UHID No: 18734
PANEL:	ylyf)	RECEIPT No:-
Mc	ofen, 0	EXAMINED ON:- 9 2

Chief Complaints:

Past	History:

DM		Nil			
Hypertension		NII	CVA	:	Nil
CAD	· Nil	Cancer	10.156	Nil	
		1811	Other		Nil

Personal History:

NEL			
1411	Activity		Active
Nil	Allergies		Nil
	: Nil : Nil	: Nil Activity : Nil Allergies	

Family History:

General Physical Examination:

Height Weight	171cm:		Pulse 6/BP	bpm bpm mmHg
Rest of e		vithin normal limit	(0 2	461

Systemic Examination:

CVS	Normal
Respiratory system	Normal
Abdominal system	Normal
CNS	Normal
Others	Normal
	Normal

PREVENTIVE HEALTH CARE SUMMARY

NAME :-	
AGE :-	UHID No:
PANEL:	RECEIPT No : -
TANED:	EXAMINED ON : -

Investigations:

All the reports of tests and investigations are attached herewith

liny

Recommendation:

Repeat Electrolytes
Cep Absolute women 102 r 3 months
My vite D3 60 k once exceely
2 months
Rein the Ports

0.67-25Hz AC50 25mm/s				ID: 18734 SHEETAL SHARMA Female 41Years Req. No. :
10mm/mV			l javr	09-03-2024 HR P P PR QRS QRS QT/QTcBz P/QRS/T RV5/SV1
4*2.5s+1r V2.22 SE	>	<u> </u>		14:44:41 : 73 bpm : 91 ms : 157 ms : 82 ms : 395/436 ms : 83/58/66 °°
SEMIP V1.92 APOLLO SPECI		Y	Report Confirmed by:	Diagnosis Information: Sinus Arrhythmia Larged PtfVI Right Atrial Enlargement
APOLLO SPECIALTY HOSPITALS			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	TMCOMA DE P B BBB



NAME:	SHEETAL SHARMA	AGE/SEX:	41	YRS./F
UHID:	18734			
REF BY:	APOLLO SPECTRA	DATE:-	09.03.	2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and echotexture. Intrahepatic biliary radicles are not dilated. No focal or diffuse lesion is seen. CBD and portal vein are normal in caliber.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 6.7 x 3.6 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 6.1 mm

Both ovaries are normal in size, shape and echotexture.

Right ovary: 2.2 x cm Left ovary: 2.3 x 1.7 cm

No obvious adenexal mass is seen. No free fluid seen.

IMPRESSION: NO SIGNIFICANT ABNORMALITY.

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRACONSULTANT RADIOLOGIST

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Dr. Prachi Sharma

BDS, MDS - Prosthodontics and Crown & Bridge DDC No: A-14151



For Appointment: +91 11 4046 5555

Mob.: +91 9910995018

Email: drusha.maheshwari@apollospectra.com

09/03/2024,

Mrs. Sheela Shalma, 414 Female.

C/C! Regular Dental

7-8 years back RCT & brown

· Calculus 1 .

Carrons ment

Soulsed !- OPG.

Ky. Warm Salt Water Reuses

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

CIN - U85100TG2009PTC099414

Regd. Office: 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040-4904 7777 | www.apollohl.com

09/0/24

Mrs. Sheeter



Slama 411-

JAGB Sel12 Macdod)

do - Bearing

Moralla N

RAJOB - 1.0/-1.0 x qc - colc

Cal hora & OS Rup

you roly

Ady Poessibed Celan
- Liber Ege Sch 00.

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -11 0048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



: Mrs. Sheetal Sharma

UHID Conducted By:

: SCHI.0000018734 : Dr. MUKESH K GUPTA

Referred By

: SELF

Age

OP Visit No Conducted Date : 41 Y/F

: SCHIOPV27217 : 09-03-2024 17:00

Protocol

Medication

Target Heart Rate Heart Rate Achieved

Percentage of THR Achieved Maximum Blood Pressure Total Exercise Duration

Maximum Worked Attained Reason for termination

Bruce Protocol

179 BPM 171 BPM

130/84 mmHg 06:04 Min. 07.00 Mets Max HR attained.

Comments

- Basal ECG NSR.
- Appropriate HR response.
- Appropriate BP response.
- No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period.
- No crepts or rhonchi.
- Arrhythmia none.
- Chest pain absent.

Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically Not valid for medico legal purpose. & Meany

Dr. M K Gupta M.B.B.S, MD, FIACM Senior Consultant Cardiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

						ę	4.								Page	1/1
APOLLO SPECT NEHRU ENCLA NEW DELHI			ē.				***	Station Telepho		4)						
NEW DEEM				EXI	ERCIS	SE STI	RESS	TEST	REPO	ORT						
Patient Name: SF Patient ID: 18734 Height: 171 cm Weight: 42.5 kg		A, SH	ЕЕТА	L			Age: 4	r: Female	3							
Study Date: 09.03 Test Type: Protocol: BRUCE							Attend	ing Physic ing Physic ician:								
Medications:																
Medical History:																
Reason for Ex	ercise	Tes	<u>t:</u>													
Exercise Test	Sumn	nary														
Phase Name	Stage N	lame		me Stage	Speed [mph]	Grade [%]	HR [bpm]	BP [mmHg]		ent						
PRETEST	SUPIN STAND HYPER	OING RV.	00	2:45 0:42 0:02	0.00 0.00 0.00	0.00 0.00 0.00	116 104 104	100/65								
EXERCISE	WARN STAGE STAGE	2	03 03	0:11 3:00 3:00 0:05	0.20 1.70 2.50 2.70	0.00 10.00 12.00 13.10	100 127 166 169	100/65 130/84								
RECOVERY	STAGE	, ,		1:13	0.00	0.00	88	130/84								
The patient ex The resting he maximal, age- pressure of 13	art rat	te of cted	75 br heart	om ros rate. Ti	e to a n he resti	naximal ng blood	heart r I press	ate of 17 ure of 10	'1 bpm. 00/65 m	This y mHg ,	value , rose	repre	sents	95	% 0	the
<u>Interpretation</u>																
Summary: Ch	est Pa	in: n	one.													
Conclusions																

Physician

Patient ID: 18734 09.03.2024 Fe 4:13:38pm 41

Female 171 cm 42.5 kg

Meds: 41 yrs Indian SHARMA, SHEETAL

BRUCE: Exercise Time 06:04
Max HR: 171 bpm 95 % of max predicted 179 bpm HR at rest: 75
Max BP: 130/84 mmHg BP at rest: 100/65 Max RPP: 22230 mmHg*bpm

	Ref. MD: Ordering MD: HK reserve used: 84 % HR recovery: 39 bpm
ST/HR index: 0:27 µV/bpm	

	Phase Name	PRETEST	EXERCISE	RECOVERY
Ref. MD: Ordering MD Technician: Test Type: Comment:	Stage Name	SUPINE STANDING HYPERV.	STAGE 1 STAGE 2 STAGE 3	
rdering MD: Test Type:	Time in Stage	02:45 00:42 06:02	03:00 03:00 00:05	04:13
	Speed [mph]	0.00 0.00 0.20	1.70 2.50 2.70	0.00
	Grade	0.00 0.00 0.00	10.00 12.00 13.10	0.00
	Workload	0.1.0	7.0 7.0	1.0
	HR HR	104 104 100	127 166 169	88
HR recovery: 39 bpm VE recovery: 1 VE/min ST/HR hysteresis: 0.003 QRS duration: BASELI Reasons for Terminat Summary: Chest Pain: none. Room: Location: *0 *	BP [100/65	130/84	130/84
HR recovery: 39 bpm VE recovery: 1 VE/min VE recovery: 1 VE/min VE/Recovery: 1 VE/min VE/Reasons for Termination: Max HR attained Summary: Chest Pain: none. Room: Room: ROOM: RPP RPP VE STLevel	RPP [mmHg*bp	10400 10400 10400	21580 21970	11440
mV (V2) NE: 90 n on: Max	VE [/min]	000-	000	c
	VE STLeve Comment [/min] III [mm]	-0.95 -0.95	-0.95 -1.05	-0.45

Attending MD:

Patient Name : Mrs. Sheetal Sharma Age : 41 Y/F

UHID : SCHI.0000018734 OP Visit No : SCHIOPV27217 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-03-2024 17:06

Referred By : SELF

Protocol : Bruce Protocol

Medication :

Target Heart Rate:179 BPMHeart Rate Achieved:171 BPMPercentage of THR Achieved:95%

Maximum Blood Pressure:130/84 mmHgTotal Exercise Duration:06:04 Min.Maximum Worked Attained:07.00 MetsReason for termination:Max HR attained.

Comments

- Basal ECG NSR.
- Appropriate HR response.
- Appropriate BP response.
- No significant changes with standing and hyperventilation.
- Good exercise tolerance.
- No significant ST segment depression over baseline during exercise or recovery period.
- No crepts or rhonchi.
- Arrhythmia none.
- Chest pain absent.

Summary

- Test is negative for provocable myocardial ischemia.
- Good exercise tolerance.
- Appropriate BP response.

Please correlate clinically Not valid for medico legal purpose.

> Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist

Patient Name : Mrs. Sheetal Sharma Age : 41 Y/F

UHID : SCHI.0000018734 OP Visit No : SCHIOPV27217 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-03-2024 17:06

Referred By : SELF

Patient Name : Mrs. Sheetal Sharma Age : 41 Y/F

UHID : SCHI.0000018734 OP Visit No : SCHIOPV27217

Conducted By: : Conducted Date :

Referred By : SELF

Patient Name : Mrs. Sheetal Sharma Age : 41 Y/F

UHID : SCHI.0000018734 OP Visit No : SCHIOPV27217

Conducted By : Conducted Date :

Referred By : SELF